Latest News
EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer
19 February 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Thursday that the European Medicines Agency has validated a Type II variation application for Enhertu (trastuzumab deruxtecan) as monotherapy for adults with...
Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons
19 February 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, on Thursday reported positive second-season results from the Phase 3 SMART trial evaluating Enflonsia (clesrovimab) in infants and chi...
IBA and Shreeji sign agreement to deploy four cyclotrons for PET radiopharmaceuticals in India
19 February 2026 - Particle accelerator technology company Ion Beam Applications S.A. (IBA) (Euronext Brussels:IBAB) on Thursday announced a new agreement with Shreeji Imaging and Diagnostic Centre Pvt Ltd, an Indian manufacturer and distributor of f...
AVEO Oncology completes first interim analysis in global Phase 3 FIERCE-HN study
19 February 2026 - US-based AVEO Oncology, an LG Chem (KRX:051910) company, announced on Wednesday that the 20mg/kg dose of ficlatuzumab has been chosen for the combination arm of the Phase 3 registrational FIERCE-HN clinical trial following the plan...
Cedar Health Research opens new embedded research site within Texas Native Health
19 February 2026 - Cedar Health Research, a Texas-based clinical trial network focused on underserved patients, and Texas Native Health, a Dallas nonprofit serving American Indian and Alaska Native communities, announced on Wednesday that they have o...